A Review on the Role of Denosumab in Fracture Prevention

References

• ChinKY, KamaruddinAA, LowNY, Ima-NirwanaS. Effects of age, sex, and ethnicity on bone health status of the elderly in Kuala Lumpur, Malaysia. Clin Interventions Aging. 2016;11:767–773. doi:10.2147/CIA.S108772
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Belgium May: Brussels; 2004:5–7.
   Google Scholar
• BlainH, MasudT, Dargent-MolinaP, et al. A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement. J Nutr Health Aging. 2016;20(6):647–652. doi:10.1007/s12603-016-0741-y27273355
   PubMed Web of Science ®Google Scholar
• RauCS, LinTS, WuSC, et al. Geriatric hospitalizations in fall-related injuries. Scandinavian J Trauma, Resuscitation Emergency Med. 2014;22:63. doi:10.1186/s13049-014-0063-1
   PubMed Web of Science ®Google Scholar
• MatityahuA, ElsonJ, MorshedS, MarmorM. Survivorship and severe complications are worse for octogenarians and elderly patients with pelvis fractures as compared to adults: data from the national trauma data bank. J Osteoporos. 2012;2012:475739. doi:10.1155/2012/47573923209945
   PubMedGoogle Scholar
• OngT, KantachuvesiriP, SahotaO, GladmanJRF. Characteristics and outcomes of hospitalized patients with vertebral fragility fractures: a systematic review. Age Ageing. 2018;47(1):17–25. doi:10.1093/ageing/afx07929253103
   PubMed Web of Science ®Google Scholar
• BauerK, SchwarzkopfL, GraesselE, HolleR. A claims data-based comparison of comorbidity in individuals with and without dementia. BMC Genetics. 2014;14:10.
   Google Scholar
• MadhavanMV, GershBJ, AlexanderKP, GrangerCB, StoneGW. Coronary artery disease in patients >/=80 years of age. J Am Coll Cardiol. 2018;71(18):2015–2040. doi:10.1016/j.jacc.2017.12.06829724356
   PubMed Web of Science ®Google Scholar
• NazrunAS, TzarMN, MokhtarSA, MohamedIN. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Therapeutics Clin Risk Management. 2014;10:937–948. doi:10.2147/TCRM.S72456
   PubMed Web of Science ®Google Scholar
• YooJ-I, HaY-C, ParkKS, KimR-B, SeoS-H, KooK-H. Incidence and mortality of osteoporotic refractures in korea according to nationwide claims data. Yonsei Med J. 2019;60(10):969–975. doi:10.3349/ymj.2019.60.10.96931538432
   PubMed Web of Science ®Google Scholar
• CosmanF, de BeurSJ, LeBoffMS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis Int. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-2
   PubMed Web of Science ®Google Scholar
• UnnanuntanaA, GladnickBP, DonnellyE, LaneJM. The assessment of fracture risk. J Bone Joint Surgery. American Volume. 2010;92(3):743–753. doi:10.2106/JBJS.I.00919
   PubMed Web of Science ®Google Scholar
• ChenYC, LinWC. Poor 1st-year adherence to anti-osteoporotic therapy increases the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures. Patient Preference Adherence. 2017;11:839–843. doi:10.2147/PPA.S13156428490865
   PubMed Web of Science ®Google Scholar
• LemsWF, RatermanHG. Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs. Therapeutic Adv Musculoskeletal Disease. 2017;9(12):299–316. doi:10.1177/1759720X17732562
   PubMed Web of Science ®Google Scholar
• van den BerghJP, van GeelTA, GeusensPP. Osteoporosis, frailty and fracture: implications for case finding and therapy. Nature Reviews. Rheumatology. 2012;8(3):163–172. doi:10.1038/nrrheum.2011.21722249162
   PubMed Web of Science ®Google Scholar
• KostenuikPJ, NguyenHQ, McCabeJ, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Mineral Res. 2009;24(2):182–195. doi:10.1359/jbmr.081112
   PubMed Web of Science ®Google Scholar
• KearnsAE, KhoslaS, KostenuikPJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocrine Reviews. 2008;29(2):155–192.18057140
   PubMed Web of Science ®Google Scholar
• LewieckiEM, BilezikianJP. Denosumab for the treatment of osteoporosis and cancer-related conditions. Clin Pharmacology Therapeutics. 2012;91(1):123–133. doi:10.1038/clpt.2011.268
   PubMed Web of Science ®Google Scholar
• SanchezA, BrunLR, SalerniH, et al. Effect of denosumab on bone mineral density and markers of bone turnover among postmenopausal women with osteoporosis. J Osteoporos. 2016;2016:8738959. doi:10.1155/2016/873895927579211
   PubMedGoogle Scholar
• DeeksED. Denosumab: a review in postmenopausal osteoporosis. Drugs Aging. 2018;35(2):163–173. doi:10.1007/s40266-018-0525-729435849
   PubMed Web of Science ®Google Scholar
• TsourdiE, LangdahlB, Cohen-SolalM, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–17. doi:10.1016/j.bone.2017.08.00328789921
   PubMed Web of Science ®Google Scholar
• YanbeiyZA, HansenKE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Design, Development Therapy. 2019;13:2843–2852. doi:10.2147/DDDT.S148654
   PubMed Web of Science ®Google Scholar
• BridgemanMB, PathakR. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin Therapeutics. 2011;33(11):1547–1559. doi:10.1016/j.clinthera.2011.10.008
   PubMed Web of Science ®Google Scholar
• WenselTM, IranikhahMM, WilbornTW. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Pharmacotherapy. 2011;31(5):510–523. doi:10.1592/phco.31.5.51021923432
   PubMed Web of Science ®Google Scholar
• BehanovaM, ReichardtB, StammTA, ZwerinaJ, KlaushoferK, KocijanR. Treatment effects of bisphosphonates and denosumab on survival and refracture from real-world data of hip-fractured patients. Calcif Tissue Int. 2019;105(6):630–641. doi:10.1007/s00223-019-00611-331531720
   PubMed Web of Science ®Google Scholar
• PedersenAB, Heide-JorgensenU, SorensenHT, Prieto-AlhambraD, EhrensteinV. Comparison of risk of osteoporotic fracture in denosumab vs alendronate treatment within 3 years of initiation. JAMA Network Open. 2019;2(4):e192416. doi:10.1001/jamanetworkopen.2019.241631002319
   PubMed Web of Science ®Google Scholar
• BoneHG, WagmanRB, BrandiML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomized FREEDOM trial and open-label extension. Lancet Diab Endocrinol. 2017;5(7):513–523. doi:10.1016/S2213-8587(17)30138-9
   PubMed Web of Science ®Google Scholar
• CummingsSR, San MartinJ, McClungMR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England J Med. 2009;361(8):756–765. doi:10.1056/NEJMoa080949319671655
   PubMed Web of Science ®Google Scholar
• FerrariS, AdachiJD, LippunerK, et al. Further reductions in non-vertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporosis Int. 2015;26(12):2763–2771. doi:10.1007/s00198-015-3179-x
   PubMed Web of Science ®Google Scholar
• PapapoulosS, ChapurlatR, LibanatiC, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Mineral Res. 2012;27(3):694–701. doi:10.1002/jbmr.1479
   PubMed Web of Science ®Google Scholar
• PapapoulosS, LippunerK, RouxC, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis Int. 2015;26(12):2773–2783. doi:10.1007/s00198-015-3234-7
   PubMed Web of Science ®Google Scholar
• BilezikianJP, LinCJF, BrownJP, et al. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group. Osteoporosis Int. 2019;30(9):1855–1864. doi:10.1007/s00198-019-05020-8
   PubMed Web of Science ®Google Scholar
• KendlerDL, ChinesA, BrandiML, et al. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporosis Int. 2019;30(1):71–78. doi:10.1007/s00198-018-4687-2
   PubMed Web of Science ®Google Scholar
• AustinM, YangYC, VittinghoffE, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and non-vertebral fractures. J Bone Mineral Res. 2012;27(3):687–693. doi:10.1002/jbmr.1472
   PubMed Web of Science ®Google Scholar
• BoonenS, AdachiJD, ManZ, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metabolism. 2011;96(6):1727–1736. doi:10.1210/jc.2010-2784
   PubMed Web of Science ®Google Scholar
• JamalSA, LjunggrenO, Stehman-BreenC, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Mineral Res. 2011;26(8):1829–1835. doi:10.1002/jbmr.403
   PubMed Web of Science ®Google Scholar
• McCloskeyEV, JohanssonH, OdenA, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Mineral Res. 2012;27(7):1480–1486. doi:10.1002/jbmr.1606
   PubMed Web of Science ®Google Scholar
• McClungMR, BoonenS, TorringO, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Mineral Res. 2012;27(1):211–218. doi:10.1002/jbmr.536
   PubMed Web of Science ®Google Scholar
• SimonJA, RecknorC, MoffettAH Jr, et al. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause. 2013;20(2):130–137. doi:10.1097/GME.0b013e318267f90923010883
   PubMed Web of Science ®Google Scholar
• GnantM, PfeilerG, DubskyPC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomized, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–443. doi:10.1016/S0140-6736(15)60995-326040499
   PubMed Web of Science ®Google Scholar
• NakamuraT, MatsumotoT, SugimotoT, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metabolism. 2014;99(7):2599–2607. doi:10.1210/jc.2013-4175
   PubMed Web of Science ®Google Scholar
• CosmanF, CrittendenDB, AdachiJD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. New England J Med. 2016;375(16):1532–1543. doi:10.1056/NEJMoa160794827641143
   PubMed Web of Science ®Google Scholar
• MiyauchiA, DinavahiRV, CrittendenDB, et al. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos. 2019;14(1):59. doi:10.1007/s11657-019-0608-z31168657
   PubMed Web of Science ®Google Scholar
• SaagKG, WagmanRB, GeusensP, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomized, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diab Endocrinol. 2018;6(6):445–454. doi:10.1016/S2213-8587(18)30075-5
   PubMed Web of Science ®Google Scholar
• SaagKG, PannacciulliN, GeusensP, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019;71(7):1174–1184. doi:10.1002/art.4087430816640
   PubMed Web of Science ®Google Scholar
• BellAD, BellBR. The FREEDOM trial is family medicine ready for biologic therapies? Canadian Family Physician • Le Médecin De Famille Canadien. 2011;57:438–441.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to evaluate denosumab in the treatment of postmenopausal osteoporosis; 2020 Available from:https://clinicaltrials.gov/ct2/show/record/NCT00089791. Accessed 39, 2020.
   Google Scholar
• PalaciosS, Kalouche-KhalilL, RizzoliR, et al. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric. 2015;18(6):805–812. doi:10.3109/13697137.2015.104548426029985
   PubMed Web of Science ®Google Scholar
• LindsayR, KregeJH, MarinF, JinL, StepanJJ. Teriparatide for osteoporosis: importance of the full course. Osteoporosis Int. 2016;27(8):2395–2410. doi:10.1007/s00198-016-3534-6
   PubMed Web of Science ®Google Scholar
• DempsterDW, ZhouH, ReckerRR, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016;101(4):1353–1363. doi:10.1210/jc.2015-418126859106
   PubMed Web of Science ®Google Scholar
• DengJ, SilverZ, HuangE, et al. Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatology. 2020. doi:10.1093/rheumatology/keaa228
   PubMed Web of Science ®Google Scholar
• TsaiJN, UihleinAV, LeeH, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial. Lancet. 2013;382(9886):50–56. doi:10.1016/S0140-6736(13)60856-923683600
   PubMed Web of Science ®Google Scholar
• LederBZ, TsaiJN, UihleinAV, et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694–1700. doi:10.1210/jc.2013-444024517156
   PubMed Web of Science ®Google Scholar
• VahleJL, LongGG, SanduskyG, WestmoreM, MaYL, SatoM. Bone neoplasms in F344 rats given teriparatide [rhPTH (1-34)] are dependent on duration of treatment and dose. Toxicologic Pathology. 2004;32(4):426–438. doi:10.1080/0192623049046213815204966
   PubMed Web of Science ®Google Scholar
• VahleJL, SatoM, LongGG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicologic Pathology. 2002;30(3):312–321. doi:10.1080/0192623025292988212051548
   PubMed Web of Science ®Google Scholar
• CosmanF, NievesJW, ZionM, et al. Daily or cyclical teriparatide treatment in women with osteoporosis on no prior therapy and women on alendronate. J Clin Endocrinol Metab. 2015;100(7):2769–2776. doi:10.1210/jc.2015-171525961136
   PubMed Web of Science ®Google Scholar
• CosmanF, McMahonD, DempsterD, NievesJW. Standard versus cyclic teriparatide and denosumab treatment for osteoporosis: a randomized trial. J Bone Mineral Res. 2020;35(2):219–225. doi:10.1002/jbmr.3850
   PubMed Web of Science ®Google Scholar
• LederBZ, TsaiJN, UihleinAV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomized controlled trial. Lancet. 2015;386(9999):1147–1155. doi:10.1016/S0140-6736(15)61120-526144908
   PubMed Web of Science ®Google Scholar
• TsaiJN, JiangLA, LeeH, HansD, LederBZ. Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-switch: a randomized controlled trial. J Clin Densitometry. 2017;20(4):507–512. doi:10.1016/j.jocd.2017.05.007
   PubMed Web of Science ®Google Scholar
• GuanabensN, Moro-AlvarezMJ, CasadoE, et al. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. Endocrine. 2019;64(3):441–455. doi:10.1007/s12020-019-01919-830963388
   PubMed Web of Science ®Google Scholar
• IranikhahM, DeasC, MurphyP, FreemanMK. Effects of denosumab after treatment discontinuation: A review of the literature. Consultant Pharmacist. 2018;33(3):142–151. doi:10.4140/TCP.n.2018.14229720299
   PubMed Web of Science ®Google Scholar
• BoneHG, BologneseMA, YuenCK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–980. doi:10.1210/jc.2010-150221289258
   PubMed Web of Science ®Google Scholar
• CummingsSR, FerrariS, EastellR, et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Mineral Res. 2017;33(2):190–198. doi:10.1002/jbmr.3337
   PubMed Web of Science ®Google Scholar
• McClungMR, WagmanRB, MillerPD, WangA, LewieckiEM. Observations following discontinuation of long-term denosumab therapy. Osteoporosis Int. 2017;28(5):1723–1732. doi:10.1007/s00198-017-3919-1
   PubMed Web of Science ®Google Scholar
• Sosa HenriquezM, Gómez de Tejada RomeroMJ, Escudero-SocorroM, et al. Hip fractures following denosumab discontinuation: three clinical cases reports. J Royal Soc Med. 2019;112(11):472–475. doi:10.1177/0141076819861027
   PubMed Web of Science ®Google Scholar
• Tripto-ShkolnikL, FundN, RouachV, ChodickG, ShalevV, GoldshteinI. Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone. 2020;130:115150. doi:10.1016/j.bone.2019.11515031715340
   PubMed Web of Science ®Google Scholar
• MillerPD, WagmanRB, PeacockM, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a Phase 2 clinical trial. J Clin Endocrinol Metabolism. 2011;96(2):394–402. doi:10.1210/jc.2010-1805
   PubMed Web of Science ®Google Scholar
• AnastasilakisAD, EvangelatosG, MakrasP, IliopoulosA. Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. Bone Reports. 2020;12:100267. doi:10.1016/j.bonr.2020.10026732373677
   PubMedGoogle Scholar
• Gonzalez-RodriguezE, Aubry-RozierB, StollD, ZamanK, LamyO. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treatment. 2020;179(1):153–159. doi:10.1007/s10549-019-05458-8
   PubMed Web of Science ®Google Scholar
• NiimiR, KonoT, NishiharaA, HasegawaM, KonoT, SudoA. Second rebound-associated vertebral fractures after denosumab discontinuation. Arch Osteoporos. 2020;15(1):7. doi:10.1007/s11657-019-0676-031898803
   PubMed Web of Science ®Google Scholar
• AnastasilakisAD, MakrasP. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporosis Int. 2016;27(5):1929–1930. doi:10.1007/s00198-015-3459-5
   PubMed Web of Science ®Google Scholar
• AnastasilakisAD, PolyzosSA, MakrasP, Aubry-RozierB, KaouriS, LamyO. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Mineral Res. 2017;32(6):1291–1296. doi:10.1002/jbmr.3110
   PubMed Web of Science ®Google Scholar
• AnastasilakisAD, YavropoulouMP, MakrasP, et al. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. European J Endocrinol. 2017;176(6):677–683. doi:10.1530/EJE-16-102728283537
   PubMed Web of Science ®Google Scholar
• FassioA, AdamiG, BeniniC, et al. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone. 2019;123:191–195. doi:10.1016/j.bone.2019.03.01930910600
   PubMed Web of Science ®Google Scholar
• Jahn-RickertK, WolfelEM, JobkeB, et al. Elevated bone hardness under denosumab treatment, with persisting lower osteocyte viability during discontinuation. Front Endocrinol. 2020;11:250. doi:10.3389/fendo.2020.00250
   PubMed Web of Science ®Google Scholar
• MillerPD, BologneseMA, LewieckiEM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–229. doi:10.1016/j.bone.2008.04.00718539106
   PubMed Web of Science ®Google Scholar
• LarocheM, CoutureG, Ruyssen-WitrandA, ConstantinA, DegboeY. Effect of risedronate on bone loss at discontinuation of denosumab. Bone Reports. 2020;13:100290. doi:10.1016/j.bonr.2020.10029032715031
   PubMedGoogle Scholar
• AdamiG, GiolloA, RossiniM, et al. Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. Reumatismo. 2020;72(2):71–74. doi:10.4081/reumatismo.2020.126732700872
   PubMed Web of Science ®Google Scholar
• KendlerD, ChinesA, ClarkP, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab. 2020;105:3. doi:10.1210/clinem/dgz095
   Web of Science ®Google Scholar
• UebelhartB, RizzoliR, FerrariSL. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporosis Int. 2017;28(9):2701–2705. doi:10.1007/s00198-017-4080-6
   PubMed Web of Science ®Google Scholar
• WilckenN, Inkyung LeeC. In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fractures. Annals of Internal Medicine. 2015;163(6):Jc11. doi:10.7326/ACPJC-2015-163-6-011
   PubMed Web of Science ®Google Scholar